(EOLS) Evolus - Overview
Stock: Botulinum Toxin, Hyaluronic Acid Injectables
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 55.4% |
| Relative Tail Risk | -11.7% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.53 |
| Alpha | -84.71 |
| Character TTM | |
|---|---|
| Beta | 1.193 |
| Beta Downside | 1.282 |
| Drawdowns 3y | |
|---|---|
| Max DD | 74.79% |
| CAGR/Max DD | -0.28 |
Description: EOLS Evolus December 26, 2025
Evolus, Inc. (NASDAQ:EOLS) is a cash-pay aesthetic-beauty company that markets its products in the United States, Canada, Europe, and Australia. Its flagship offering is Jeuveau, a 900-kilodalton purified botulinum toxin type A indicated for temporary reduction of moderate-to-severe glabellar lines, complemented by the Evolysse line of injectable hyaluronic-acid gels.
Key performance metrics from the most recent 10-Q (Q3 2024) show net sales of $84.3 million, a 12% year-over-year increase driven primarily by higher Jeuveau volume, and an adjusted EBITDA margin of roughly 22%, indicating a relatively high-margin business within the aesthetic sector.
The cash-pay aesthetic market is expanding at an estimated 7–9% CAGR globally, propelled by rising disposable income, increasing consumer acceptance of non-surgical cosmetic procedures, and a demographic shift toward younger adults seeking preventative treatments. Evolus’s reliance on a single proprietary neuromodulator makes product-line concentration a material risk that investors should monitor.
For a deeper quantitative assessment of Evolus’s valuation dynamics, you may find ValueRay’s analyst toolkit useful as a next step in your research.
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income: -58.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.26 > 0.02 and ΔFCF/TA -14.49 > 1.0 |
| NWC/Revenue: 23.85% < 20% (prev 36.06%; Δ -12.21% < -1%) |
| CFO/TA -0.23 > 3% & CFO -50.3m > Net Income -58.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.02 > 1.5 & < 3 |
| Outstanding Shares: last quarter (64.7m) vs 12m ago 2.50% < -2% |
| Gross Margin: 65.83% > 18% (prev 0.68%; Δ 6515 % > 0.5%) |
| Asset Turnover: 127.4% > 50% (prev 108.2%; Δ 19.28% > 0%) |
| Interest Coverage Ratio: -1.80 > 6 (EBITDA TTM -29.3m / Interest Expense TTM 20.3m) |
Altman Z'' -11.70
| A: 0.31 (Total Current Assets 134.9m - Total Current Liabilities 66.7m) / Total Assets 219.0m |
| B: -3.02 (Retained Earnings -661.2m / Total Assets 219.0m) |
| C: -0.16 (EBIT TTM -36.5m / Avg Total Assets 224.3m) |
| D: -2.67 (Book Value of Equity -661.3m / Total Liabilities 247.8m) |
| Altman-Z'' Score: -11.70 = D |
Beneish M -2.89
| DSRI: 0.98 (Receivables 50.4m/44.6m, Revenue 285.8m/248.3m) |
| GMI: 1.04 (GM 65.83% / 68.14%) |
| AQI: 1.09 (AQ_t 0.33 / AQ_t-1 0.30) |
| SGI: 1.15 (Revenue 285.8m / 248.3m) |
| TATA: -0.04 (NI -58.6m - CFO -50.3m) / TA 219.0m) |
| Beneish M-Score: -2.89 (Cap -4..+1) = A |
What is the price of EOLS shares?
Over the past week, the price has changed by -4.05%, over one month by -23.86%, over three months by -37.33% and over the past year by -66.44%.
Is EOLS a buy, sell or hold?
- StrongBuy: 4
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the EOLS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 17 | 277.8% |
| Analysts Target Price | 17 | 277.8% |
| ValueRay Target Price | 4 | -12.2% |
EOLS Fundamental Data Overview February 03, 2026
P/S = 1.0636
P/B = 53.7058
Revenue TTM = 285.8m USD
EBIT TTM = -36.5m USD
EBITDA TTM = -29.3m USD
Long Term Debt = 145.8m USD (from longTermDebt, last quarter)
Short Term Debt = 2.48m USD (from shortTermDebt, last quarter)
Debt = 154.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 111.4m USD (from netDebt column, last quarter)
Enterprise Value = 415.4m USD (304.0m + Debt 154.9m - CCE 43.5m)
Interest Coverage Ratio = -1.80 (Ebit TTM -36.5m / Interest Expense TTM 20.3m)
EV/FCF = -7.37x (Enterprise Value 415.4m / FCF TTM -56.4m)
FCF Yield = -13.57% (FCF TTM -56.4m / Enterprise Value 415.4m)
FCF Margin = -19.72% (FCF TTM -56.4m / Revenue TTM 285.8m)
Net Margin = -20.49% (Net Income TTM -58.6m / Revenue TTM 285.8m)
Gross Margin = 65.83% ((Revenue TTM 285.8m - Cost of Revenue TTM 97.7m) / Revenue TTM)
Gross Margin QoQ = 66.47% (prev 65.31%)
Tobins Q-Ratio = 1.90 (Enterprise Value 415.4m / Total Assets 219.0m)
Interest Expense / Debt = 2.64% (Interest Expense 4.09m / Debt 154.9m)
Taxrate = 21.0% (US default 21%)
NOPAT = -28.8m (EBIT -36.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.02 (Total Current Assets 134.9m / Total Current Liabilities 66.7m)
Debt / Equity = -5.39 (negative equity) (Debt 154.9m / totalStockholderEquity, last quarter -28.8m)
Debt / EBITDA = -3.80 (negative EBITDA) (Net Debt 111.4m / EBITDA -29.3m)
Debt / FCF = -1.98 (negative FCF - burning cash) (Net Debt 111.4m / FCF TTM -56.4m)
Total Stockholder Equity = -12.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -26.11% (Net Income -58.6m / Total Assets 219.0m)
RoE = 483.0% (negative equity) (Net Income TTM -58.6m / Total Stockholder Equity -12.1m)
RoCE = -27.32% (EBIT -36.5m / Capital Employed (Equity -12.1m + L.T.Debt 145.8m))
RoIC = -23.74% (negative operating profit) (NOPAT -28.8m / Invested Capital 121.5m)
WACC = 7.53% (E(304.0m)/V(458.9m) * Re(10.31%) + D(154.9m)/V(458.9m) * Rd(2.64%) * (1-Tc(0.21)))
Discount Rate = 10.31% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 6.33%
Fair Price DCF = unknown (Cash Flow -56.4m)
EPS Correlation: 40.49 | EPS CAGR: 43.70% | SUE: -0.83 | # QB: 0
Revenue Correlation: 94.72 | Revenue CAGR: 20.14% | SUE: 0.30 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.09 | Chg30d=-0.020 | Revisions Net=-1 | Analysts=3
EPS next Year (2026-12-31): EPS=0.06 | Chg30d=-0.106 | Revisions Net=+0 | Growth EPS=+116.8% | Growth Revenue=+11.8%